Read-Gene SA

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: PLRADGN00014
PLN
5.50
0.12 (2.23%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Read-Gene SA stock-summary
stock-summary
Read-Gene SA
Pharmaceuticals & Biotechnology
Read-Gene SA is a Poland-based company active in the biotechnology sector. It is focused on technologies which aim is to detect, prevent and treat malignant tumors. The Company specializes in three fields: chemoprevention, clinical trials and genetic testing. It offers breast cancer, colon cancer and prostate cancer tests, as well as, medical consultancy, DNA tests and supplements. The Company operates one wholly owned subsidiary, Dieta Antyrakowa Read-Gene Sp. z o.o. Its major shareholder is GEN-PAT-MED Sp. z o.o.
Company Coordinates stock-summary
Company Details
Ul. Akacjowa 2 , SZCZECIN None : 71-253
stock-summary
Tel: 48 91 433425648 91 4334256
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Bronislaw Ziemianin
Chairman of the Supervisory Board
Mr. Tomasz Huzarski
Vice Chairman of the Supervisory Board
Mr. Adam Gliszczynski
Member of the Supervisory Board
Mr. Jacek Gronwald
Member of the Supervisory Board
Mr. Janusz Pirog
Member of the Supervisory Board
Mr. Adam Szuba
Member of the Supervisory Board
Mr. Dariusz Wiecaszek
Member of the Supervisory Board
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
3 Million
(Quarterly Results - Jun 2025)
Net Profit:
0 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

PLN Million (Micro Cap)

stock-summary
P/E

0

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

4.71

stock-summary
Return on Equity

1.55%

stock-summary
Price to Book

0.00